Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
A minimalist illustration of a pill representing drug development in biotech.

May 20, 2026

Cohere wants to break into the biotech business

Cohere is making strategic moves to enter the pharmaceutical sector by acquiring Reliant AI, a Montreal-based startup specializing in AI solutions for drug development.This acquisition marks Cohere's second significant move this year, following its merger with Aleph Alpha, a German AI firm. By integrating Reliant's technology into its in-house platform, North, Cohere aims to develop tailored AI tools specifically for biotech companies. Reliant's existing relationships with major pharmaceutical p
A minimalist illustration of a leaf and a chemical structure in a dark palette.

May 20, 2026

EVGN: Revenue fell sharply and net loss widened as focus shifted to core AI-driven pharma and ag chem

Evogene Ltd. (EVGN) reported a significant decline in revenue and an increased net loss for Q1 2026, primarily due to reduced sales from its Casterra division and rising financing costs.Despite these financial challenges, the company is maintaining its strategic emphasis on developing its AI-driven pharmaceutical and agricultural chemical products. Evogene is actively pursuing new partnerships and advancing its internal research and development efforts to bolster its core pipelines.This shift to
A minimalist illustration of a DNA strand and molecule in flat design.

May 20, 2026

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

Incyte and Genesis Molecular AI have announced a significant expansion of their collaboration aimed at enhancing drug discovery through advanced AI technologies.This partnership marks a pivotal move in the pharmaceutical industry, as it leverages Genesis' GEMS AI platform to utilize Incyte's proprietary experimental data for training large-scale foundation models. The expanded agreement builds on their initial collaboration and aims to accelerate the development of novel molecules across various
A glass vial on a lab bench in a dimly lit laboratory setting.

May 20, 2026

Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration

This week, Bristol Myers Squibb (BMS) and Incyte made headlines with significant advancements in their artificial intelligence initiatives, reflecting a broader trend in the pharmaceutical industry toward integrating AI into core operations.BMS has formed a strategic partnership with Anthropic to deploy its AI system, Claude, across various functions including research and manufacturing. This initiative aims to enhance productivity by embedding AI directly into workflows rather than just using i
RNA molecule and robotic arm illustration

May 19, 2026

Sen. David McCormick Tours AI-Powered Biotech Labs at UPenn

Senator Dave McCormick recently toured the University of Pennsylvania's AIRFoundry, an innovative AI-focused lab dedicated to transforming biotech research and drug development.This facility, supported by the National Science Foundation, integrates artificial intelligence, robotics, and automation to expedite the creation of RNA-based therapies and other biotechnological advancements. The application of these technologies has the potential to compress lengthy drug development processes into mere
A minimalist illustration of a pill and a molecule in a dark palette.

May 19, 2026

Cohere buys Montreal’s Reliant AI in pharma market push

Cohere has made a strategic acquisition by purchasing Reliant AI, a Montreal-based company focused on developing AI technology for the pharmaceutical sector, as part of its initiative to penetrate specialized markets.This acquisition grants Cohere access to a range of global biotech clients and a skilled research team based in Canada and Germany. Reliant AI has created tools designed to streamline literature reviews and enhance the drug discovery process, utilizing advanced techniques like reinf
A DNA strand on a lab bench in a dimly lit laboratory

May 19, 2026

Twist Bioscience Corp stock (US90130A1016): biotech shares under pressure despite fresh AI drug disc

Twist Bioscience Corp's stock has recently experienced a downturn despite announcing a promising AI-driven drug discovery partnership with LenioBio, raising questions about the volatility of this biotech player.On May 18, 2026, Twist Bioscience Corp's shares fell approximately 7% to close at $49.17, following a period of strong price increases. This decline occurred shortly after the company revealed its collaboration with LenioBio, aimed at integrating automated DNA manufacturing with AI-led dr
Minimalist illustration of a DNA strand and oligonucleotide in dark colors with lime accents.

May 17, 2026

InSilico Ribo Oligonucleotide Alliance Tests AI Drug Discovery Model

InSilico Medicine has partnered with Suzhou Ribo Life Science to enhance AI-driven oligonucleotide drug development.This collaboration merges InSilico's advanced automation and AI capabilities with Ribo's specialized knowledge in oligonucleotide therapies, targeting various stages of the drug discovery process, including target identification and molecule design. This strategic alliance is noteworthy as oligonucleotide therapies are gaining traction in the pharmaceutical landscape, representing
A petri dish and pipette on a lab bench

May 17, 2026

OpenAI GPT-Rosalind: Inside the 0.751 BixBench Score and $2.6B Pharma Bet [2026]

OpenAI has launched GPT-Rosalind, a specialized AI model aimed at revolutionizing the pharmaceutical research sector, which is grappling with declining productivity and soaring drug development costs. This model, named after the renowned chemist Rosalind Franklin, is designed to enhance processes such as drug discovery, genomics analysis, and translational medicine.Released on April 16, 2026, GPT-Rosalind is part of a broader initiative by OpenAI to develop life sciences models. It has achieved
A flat illustration of a molecule structure on a solid background.

May 16, 2026

Schrodinger stock (US80655G1067): AI-powered drug discovery story after latest earnings

Schrodinger's recent quarterly report highlights its dual focus on AI-driven drug discovery and software revenue, drawing significant investor interest.Schrodinger has recently updated investors with its latest earnings, showcasing its AI-powered drug discovery platform alongside a breakdown of its software and drug discovery revenues. The company operates at the intersection of computational chemistry and biotechnology, providing tools that enable pharmaceutical and materials science firms to d
A test tube with a colorful drug compound on a lab bench

May 16, 2026

AI: Revolutionising Pharma R&D

AI is significantly transforming pharmaceutical research and development, moving from a traditional one-size-fits-all model to a more personalized approach.The pharmaceutical industry is experiencing a shift towards precision medicine, largely driven by artificial intelligence (AI). This technology harnesses large datasets and predictive analytics to create tailored therapies that consider individual patient characteristics, including genetics and lifestyle. By analyzing clinical and real-world
Minimalist illustration of a protein structure in dark tones with lime accents.

May 15, 2026

Google Launches REPLIQA to Integrate Quantum AI and Life Sciences

Google has unveiled the REPLIQA initiative, a $10 million program aimed at merging quantum AI with life sciences research.The Research Program at the Intersection of Life Sciences & Quantum AI (REPLIQA) seeks to leverage quantum mechanics to tackle complex biological processes that traditional computing struggles to simulate. Funded institutions include Harvard, MIT, UC San Diego, UC Santa Barbara, and the University of Arizona. The initiative aims to explore molecular phenomena such as protein